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Abstract
Background
Social anxiety disorder is one of the most persistent and common anxiety disorders. Individ-
ually delivered psychological therapies are the most effective treatment options for adults
with social anxiety disorder, but they are associated with high intervention costs. Therefore,
the objective of this study was to assess the relative cost effectiveness of a variety of psy-
chological and pharmacological interventions for adults with social anxiety disorder.
Methods
A decision-analytic model was constructed to compare costs and quality adjusted life years
(QALYs) of 28 interventions for social anxiety disorder from the perspective of the British
National Health Service and personal social services. Efficacy data were derived from a
systematic review and network meta-analysis. Other model input parameters were based
on published literature and national sources, supplemented by expert opinion.
Results
Individual cognitive therapy was the most cost-effective intervention for adults with social
anxiety disorder, followed by generic individual cognitive behavioural therapy (CBT), phe-
nelzine and book-based self-help without support. Other drugs, group-based psychological
interventions and other individually delivered psychological interventions were less cost-
effective. Results were influenced by limited evidence suggesting superiority of
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Conclusion
Various forms of individually delivered CBT appear to be the most cost-effective options for
the treatment of adults with social anxiety disorder. Consideration of side effects of drugs
would only strengthen this conclusion, as it would improve even further the cost effective-
ness of individually delivered CBT relative to phenelzine, which was the next most cost-
effective option, due to the serious side effects associated with phenelzine. Further
research needs to determine more accurately the long-term comparative benefits and
harms of psychological and pharmacological interventions for social anxiety disorder and
establish their relative cost effectiveness with greater certainty.
Introduction
Social anxiety disorder is one of the most persistent and common anxiety disorders, with a life-
time prevalence estimated to range between 3.9% and 13.7% in Europe [1]. People with social
anxiety disorder have difficulty forming and retaining personal and social relationships [2],
have higher risk of leaving school early and obtaining poorer qualifications [3], experience
impairment in their daily functioning including work/school performance and social life [4],
and report an important reduction in their quality of life compared with people without the
disorder [5]. They also incur considerable healthcare costs, especially relating to the use of pri-
mary care services, experience high levels of productivity losses and receive higher social bene-
fits compared with people in the general population [6–8]. It has been shown that as the
number of social fears increases, so does health service utilisation [9]. The presence of comor-
bid psychiatric disorders increases usage of health services and productivity losses [6,8,9].
Several studies have assessed the clinical effectiveness of psychological and pharmacological
treatments for social anxiety disorder [10–13]. Recently, individually delivered psychological
therapies were demonstrated to be more effective than drugs and self-help for adults with social
anxiety disorder [14]. Given the variety of available interventions for the treatment of social
anxiety disorder, the high costs associated with provision of psychological interventions, and
the need for efficient use of healthcare resources under conditions of restricted budgets, the
objective of this study was to examine the cost-effectiveness of a wide range of psychological
and pharmacological interventions for the treatment of adults with social anxiety disorder
from the perspective of the British National Health Service (NHS) and Personal Social Services,
using decision-analytic modelling.
This study is an update of the economic analysis that informed the development of national
clinical guidance for social anxiety disorder in England andWales, published by the National
Institute for Health and Care Excellence (NICE) [15]. The guideline was developed by the
Guideline Development Group (GDG), a multi-disciplinary team consisting of clinical aca-
demics, health professionals and service user and carer representatives with expertise and expe-
rience in the field of social anxiety. The GDG contributed to the development of the economic
model by providing advice on issues relating to the natural history and treatment patterns of
social anxiety disorder in the UK, as well as on model inputs in areas where evidence was
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lacking. The analysis presented here utilised efficacy data from an updated systematic review
and network meta-analysis (NMA) of interventions for adults with social anxiety disorder [14].
Methods
Study population
The study population comprised adults aged at least 18 years who fulfilled diagnostic criteria
for social anxiety disorder and were eligible for all the treatment options included in the analy-
sis. Full details on the study population selection criteria are provided in a related publication
[14].
Interventions assessed
The economic analysis assessed interventions that the GDG considered as appropriate first-
line treatments for adults with social anxiety disorder, for which adequate clinical evidence was
available. The interventions evaluated in the economic analysis were selected among those
included in a recent comprehensive systematic review and NMA [14]. We evaluated the cost
effectiveness of distinct interventions, rather than classes of treatments, as there may be differ-
ences in resource implications among interventions belonging to the same class. Details on the
rationale for the selection of appropriate interventions for consideration in the economic anal-
ysis are reported in the NICE full guideline report [16]. The following interventions were
considered:
Pharmacological interventions:
• Seven selective serotonin / serotonin-noradrenergic reuptake inhibitors (SSRIs / SNRIs): cita-
lopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline and venlafaxine (pro-
longed-release formulation XL)
• Two monoamine oxidase inhibitors (MAOIs): moclobemide and phenelzine
• One anticonvulsant: pregabalin
• One noradrenergic and specific serotonergic antidepressant: mirtazapine
Psychological interventions:
• Self-help without therapist support: book-based (SHNS, book) and computer-based (SHNS,
internet), both involving minimal contact with therapists
• Self-help with therapist support: book-based (SHWS, book) and computer-based (SHWS,
internet)
• Exposure in vivo
• Mindfulness training
• Two types of group cognitive behavioural therapy: group cognitive behavioural therapy fol-
lowing the Heimberg model (GCBT Heimberg) [17]; and group cognitive behavioural ther-
apy not following a specified model (GCBT general)
• Interpersonal psychotherapy (IPT)
• Psychodynamic psychotherapy (PDPT)
• Supportive therapy
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• Four types of individually delivered cognitive behavioural therapy: individual cognitive beha-
vioural therapy following the Hope, Heimberg and Turk model (ICBT Hope) [18]; cognitive
therapy following the Clark and Wells model (ICBT C&W) [19]; cognitive therapy following
the Clark andWells model with shortened sessions (ICBT short); and individual cognitive
behavioural therapy not following a specified model (ICBT general)
The economic model also included two ‘inactive’ interventions, pill placebo and wait list, in
order to assess the cost effectiveness of active interventions versus non-specific medical man-
agement and a do-nothing option, respectively.
The economic analysis made simultaneous comparisons of all the above treatment options;
this was enabled by employing NMAmethods to synthesise available clinical evidence [20].
Economic model structure
A hybrid decision-analytic model consisting of a decision-tree followed by a two-state Markov
model was constructed using Microsoft Office Excel 2007 to assess total costs and Quality
Adjusted Life Years (QALYs) of the 28 interventions for social anxiety disorder. The model
structure, shown in Fig 1, was dictated by the natural history of the disorder, its treatment pat-
terns and associated care pathways in the UK, and the availability of relevant clinical and epide-
miological data.
The model followed hypothetical cohorts of adults with social anxiety disorder initiated on
each of the 28 interventions assessed. For purposes of estimation of QALYs, initial treatment
lasted 12 weeks for all interventions, although in trials and clinical practice the duration of psy-
chological interventions ranges between 9 and 16 weeks; this modelling assumption did not
affect estimated resource use. Following treatment, people in each cohort either recovered, no
further meeting criteria for diagnosis (thus entering a state of ‘no social anxiety disorder’) or
failed to recover (remaining in the state of ‘social anxiety disorder’). People who recoved fol-
lowing pharmacological treatment were assumed to receive another 26 weeks of maintenace
treatment with the same drug; people recovering after psychological treatment did not receive
further maintenance treatment. Those not recovering were assumed to stop treatment rather
than switch to an alternative intervention as the GDG suggested this is likely in a population
that is usually reluctant to maintain contact with health services.
During the year post-treatment, people who did not recover remained in the ‘social anxiety
disorder’ state. Those who recovered might relapse, meeting again diagnostic criteria for the
disorder, and thus re-enter the ‘social anxiety disorder’ state. From that point on all people in
each cohort entered the Markov model, which was run in yearly cycles. During each cycle peo-
ple remained in their current health state or moved between the ‘no social anxiety disorder’
Fig 1. Schematic diagram of the economicmodel constructed to assess the cost-effectiveness of
interventions for social anxiety disorder.
doi:10.1371/journal.pone.0140704.g001
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and the ‘social anxiety disorder’ states. A half-cycle correction was applied. The yearly cycles
were considered appropriate and consistent with the slow, chronic course of social anxiety dis-
order and the low rates of clinical changes in terms of recovery and relapse characterising the
disorder [21], and were selected for convenience in terms of applying annual discounting of
costs and benefits.
The time horizon of the analysis was the 12 weeks of initial treatment plus 5 years post-
treatment, comprising 1 year in the decision-tree and 4 yearly cycles in the Markov model.
This time horizon was selected to enable assessment of longer term benefits and costs associ-
ated with each intervention and to allow intervention costs to be spread over a longer time
period, over which benefits of interventions can be still potentially enjoyed. A 5-year time hori-
zon following 12 weeks of initial treatment was considered appropriate and reasonable, given
that long-term clinical data were available from a prospective naturalistic study that observed
the long-term clinical course of anxiety disorders including social anxiety disorder over
12 years [21], so there was no need for extrapolation of clinical data.
Clinical data utilised in the model
Clinical efficacy. Efficacy data were derived from a systematic literature review and NMA
of randomised controlled trials (RCTs) of interventions for adults with social anxiety disorder
[14]; the NMA, based on a random effects model [22], was conducted within a Bayesian frame-
work using Markov Chain Monte Carlo simulation techniques implemented in WinBUGS 1.4
[23,24]. The NMA included 101 trials reporting continuous data on symptom scales of social
anxiety, of which 24 also reported dichotomous recovery data (with recovery being defined as
no longer meeting criteria for diagnosis). The studies reported several continuous measures of
social anxiety, none of which were common to all trials, so treatment effects for each trial were
calculated as a standardised mean difference (SMD). Based on published psychometric proper-
ties and data from clinically referred participants who completed several measures, continuous
measures were assumed to be equally responsive and had a mean correlation of 0.65 (for details
see [14]). The outcome measures used in the clinical analysis are provided in S1 File.
The log-odds ratio of recovery was transformed into a notional SMD for recovery using the
formula LORRecovery ¼  pﬃﬃ3p SMD [25].
Following inspection of the relationship between the log-odds ratio estimated from the
SMD of continuous data and the transformed log-odds ratio of recovery data in studies report-
ing both ([14]—see Appendix 4 in Supplementary Appendix A), we assumed a linear relation-
ship between the pooled treatment effects of symptom scales and the transformed treatment
effects on recovery that was the same across all treatments, and forced the intercept at zero.
The plausibility of the assumed relationship between the log-odds ratio of the SMD of continu-
ous data and the transformed log-odds ratio of recovery data was assessed empirically by exam-
ining the relationship in the relative effects for studies reporting both outcomes, and discussed
with clinical experts who considered it reasonable.
Thus, relative treatment effects expressed as SMD versus wait list were estimated from all
studies and this correspondence (between the log-odds ratio of SMD of continuous data and
the transformed log-odds ratio of recovery data) and its uncertainty were used to borrow
strength from studies that reported recovery, and also to transform the estimates into log-odds
ratios of recovery in order to populate the economic model. These were subsequently used to
estimate absolute probabilities of recovery for each intervention using the probability of recov-
ery for wait list as baseline, which was calculated by pooling recovery data from all wait list
arms in RCTs included in the NMA. We note that the method used fully incorporates the
uncertainty in the estimates.
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The WinBUGS model was run with an initial burn-in period of 20,000 iterations, followed
by 40,000 further iterations, thinned by 4 so as to obtain 10,000 iterations for use in the eco-
nomic model. Full details of the methods and results of the systematic literature review and
NMA, including risk of bias assessment of the individual studies, the full dataset, the statistical
analysis of clinical data and the statistical code used in the NMA are provided in a related pub-
lication [14].
Other clinical input parameters. The first-year probability of relapse after recovery with a
drug was estimated using pooled data from 5 placebo-controlled pharmacological RCTs on
relapse prevention in adults with social anxiety disorder [26–30], identified by a systematic lit-
erature search; this probability was estimated to be higher that the pooled risk of relapse during
maintenance treatment in RCT active drug arms, but lower than the pooled risk of relapse of
responders to initial drug treatment who were subsequently randomised to placebo (thus not
receiving maintenance treatment); for simplicity and due to lack of more suitable data the first
year probability of relapse for drugs was assumed to equal the midpoint of the two pooled
risks. The resulting estimate, which was validated by GDG expert opinion, was utilised across
all pharmacological treatment arms of the model and pill placebo, as drug-specific relapse data
were sparse and mostly unavailable.
The first-year probability of relapse after recovery with psychological interventions was cal-
culated by dividing the first-year probability of relapse for drugs by the risk ratio of relapse of
drugs versus psychological therapies. The latter was estimated from data derived from a small
observational 12-month follow-up study [31] of responders in an RCT of phenelzine versus
group CBT for social anxiety disorder [32] and was applied to all psychological interventions
due to lack of intervention-specific relapse data.
The first-year probability of relapse after recovery in wait list was estimated using data from
a naturalistic study that reported 12-year probabilities of recovery and recurrence in adults
with social anxiety disorder estimated using survival analysis [21]. Data from this study were
also used to calculate the annual probabilities of recovery and relapse in years 2 to 5 post-
treatment (i.e. in the Markov component of the model), which were applied to all model
cohorts, regardless of initial treatment.
Utility data considered in the model
Utility scores express preferences for different states of health-related quality of life (HRQoL)
and are necessary for the estimation of QALYs. Following a systematic literature search of util-
ity data for social anxiety disorder, the economic model was populated with utility scores
obtained from a Finish national health survey [33] that reported EQ-5D utility scores (esti-
mated using the UK Time Trade-Off Tarrif) [34] for people with social anxiety disorder and
people with no mental disorder over the last 12 months. The 12-month prevalence of psychiat-
ric disorders in survey participants was assesed using the Munich version of the Composite
International Diagnostic Interview (M-CIDI) [35]. Utility scores for people with social anxiety
disorder over the previous 12 months were used for the ‘social anxiety disorder’ state. Utility
scores for people with no mental disorder over the last 12 months were used as a proxy for the
state of ‘no social anxiety disorder’, although it is acknowledged that people recovering from
social anxiety disorder may not reach the HRQoL of a person without a mental disorder, and
thus their HRQoL may have been overestimated, at least over the first few months following
recovery.
Another limitation of using these data was that diagnosis referred to a 12-month period
prior to data collection, so some survey participants might have experienced an improvement
in their condition over this period (and actually might have recovered at the point of
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interview), and thus the HRQoL associated with the ‘social anxiety disorder’ state may have
been overestimated. These limitations were deemed acceptable as no better quality utility data
were identified; moreover, since overestimation of utility scores was likely to have occurred, to
some extent, in both ‘social anxiety disorder’ and ‘no social anxiety disorder’ states, the effect of
overestimation was deemed to be, at least partially, cancelled out and to be affecting the results
of the economic analysis only insignificantly. The economic model assumed linear changes in
utility when transitioning between ‘social anxiety disorder’ and ‘no social anxiety disorder’.
Healthcare resource use and cost data
The analysis considered intervention costs and other health and personal social service costs
associated with social anxiety disorder, expressed in 2015 prices.
Pharmacological intervention costs consisted of drug acquisition and general practitioner
(GP) visit costs. The intervention cost of pill placebo comprised GP visit costs only. The aver-
age daily dosage for each drug was determined according to optimal clinical practice [36] and
was consistent with dosages reported in the RCTs that were included in the NMA. Initial drug
treatment lasted 12 weeks, followed, in people who recovered, by 26 weeks of maintenance
treatment at the same daily dosage, according to optimal practice. Initial drug treatment
included 4 GP visits; maintenance treatment for those recovering included 3 extra GP visits.
These resource use estimates were based on the GDG expert opinion and are lower than
descriptions of medical resource use in pharmacological trial protocols. Drug acquisition costs
and the GP unit cost were taken from national sources [37,38]. Active drug intervention costs,
including 7 GP visits, ranged from £339 (citalopram) to £939 (pregabalin) (Table 1).
Psychological intervention costs were calculated by combining therapists’ time (as described
in the relevant source RCTs) with respective national unit costs [39]. All therapists were
assumed to be Band 7 therapists according to the NHS Agenda for Change for qualified Allied
Health Professionals. An initial GP visit for referral to psychological services was also consid-
ered. No booster sessions were assumed as there is no evidence to indicate that these are neces-
sary for psychological treatment effect sustainment, and they are not routinely offered in
Table 1. Intervention costs of pharmacological treatments considered in the economic analysis (2015 prices).
Drug Mean daily dosage Drug cost—12 weeksa Drug cost—26 weeksa Total intervention (drug and GPb) cost—12+26 weeks
Citalopram 40 mg £3.84 £8.32 £339.43
Escitalopram 20 mg £6.21 £13.46 £346.93
Fluoxetine 40 mg £6.50 £14.07 £347.84
Fluvoxamine 150 mg £71.48 £154.88 £553.64
Mirtazapine 30 mg £4.80 £10.40 £342.47
Moclobemide 600 mg £78.34 £169.75 £575.36
Paroxetine 40 mg £12.82 £27.79 £367.88
Phenelzine 60 mg £75.60 £163.80 £566.67
Pregabalin 450 mg £193.20 £418.60 £939.07
Sertraline 200 mg £9.96 £21.58 £358.81
Venlafaxine 150 mg £52.36 £113.45 £493.08
Pill placebo NA NA NA £327.27
a Drug acquisition costs were taken from the Electronic Drug Tariff for England and Wales [37]; lowest reported price for each drug was used, including
prices of generic forms, where available.
b GP cost includes 4 GP visits during 12 weeks of initial treatment and 3 visits during the 26-week maintenance period, at £46.75 per visit = £327.25; GP
unit cost, including qualiﬁcation and direct care staff costs, was taken from [38] and inﬂated to 2015 price.
doi:10.1371/journal.pone.0140704.t001
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clinical practice. Self-help intervention costs included the cost of either a book or a computer-
ised programme and related infrastructure or equipment required for the programme delivery
(license fee or website hosting, personal computers and capital overheads). The intervention
cost of wait list was zero. Estimated psychological intervention costs for self-help interventions
ranged between £205-£912 per person; for group therapies £551-£1,148 per person; and for
individually delivered therapies £1,588-£2,359 per person (Table 2).
Adults with social anxiety disorder incur costs to health and personal social services that are
associated with their disorder. Annual health and personal social service costs associated with
social anxiety disorder were taken from a published analysis [6] of service use data obtained
from a British Psychiatric Morbidity Survey conducted in 1993–1994 [41]. These costs
included GP consultations, home visits, counselling or therapy contacts and inpatient and out-
patient secondary care, and were reported separately for people with social anxiety disorder
and people without psychiatric morbidity (the latter was assumed to correspond to the state of
‘no social anxiety disorder’). These costs were not applied during the period of initial treatment
(over which intervention costs were incurred), to avoid doublecounting of treatment costs,
which might have already been included in the estimation of health and personal social service
costs associated with the disorder, but were applied immediately after completion of initial
treatment, at the end of 12 weeks.
Costs were expressed in 2015 prices, inflated, where necessary, using the Hospital and Com-
munity Health Services pay and prices index [38]. The inflation index for year 2015 was esti-
mated using the average value of the Hospital and Community Health Services pay and prices
indices of the previous 3 years. Costs and QALYs were discounted at 3.5% annually, following
NICE guidance [42].
An overview of methods, data sources and a list of the key assumptions underpinning the
economic model are provided in S2 File.
Handling uncertainty
To account for the uncertainty around the input parameter point estimates, a probabilistic
analysis was undertaken, in which input parameters were assigned probabilistic distributions
[43]. Subsequently, 10,000 iterations were performed, each drawing random values out of the
distributions fitted onto the model input parameters. Mean costs and QALYs and the Net
Monetary Benefit (NMB) for each treatment option were calculated by averaging across the
10,000 iterations. The cost-effectiveness acceptability frontier was also plotted; this shows the
treatment option with the highest mean NMB over different cost effectiveness thresholds, and
the probability that the option with the highest NMB is the most cost-effective among those
assessed. This method of presenting uncertainty has advantages over confidence interval esti-
mation for incremental cost-effectiveness ratios, in particular in comparisons of multiple com-
peting interventions, and presents uncertainty in a format that is more relevant to decision
making [44].
The distributions of the probability of recovery for each intervention at end of treatment
were defined directly from values recorded in the 10,000 iterations of the NMA. The log-odds
of recovery on wait list was assumed to follow a normal distribution. The log-odds ratios of
recovery for each treatment relative to wait list were applied to simulated values of this normal
distribution and converted onto the probability scale. This ensured that the full posterior distri-
bution of the relative treatment effects was used to estimate the absolute probabilities of recov-
ery for each treatment [45].
Other probabilities and utility scores were assigned beta distributions. The risk ratio of
relapse was assigned a log-normal distribution. Annual health and personal social service costs
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were assigned a gamma distribution. The estimation of distribution ranges was based on
respective available data reported in the published sources of evidence.
Uncertainty in intervention costs was considered by assigning probability distributions
around the number of GP visits and therapist sessions in individiually delivered psychological
Table 2. Intervention costs of psychological treatments (2015 prices).
Intervention Resource use details Total cost per
persona
SHNS, book 75 minutes contact with therapist plus cost of book (Rapee’s
Overcoming Shyness and Social Phobia: A Step by Step Guide
current cost on Amazon: £20.66)
£205
SHNS, internet 75 minutes contact with therapist; the annual cost of internet
hosting of a self-help internet pilot programme in the UK is £14,000
(GDG information) divided by 30 people with social phobia
expected to take up the programme in an IAPT service annually
(IAPT audit of activity data provided by GDG); cost of hardware &
capital overheads £13/person (2015 price, based on [40])
£664
SHWS, book 210 minutes contact with therapist plus cost of book as above £453
SHWS, internet 210 minutes contact with therapist plus cost of internet hosting,
hardware and capital overheads as above
£912
Exposure 12 group sessions x 2.5 hours each, 2 therapists & 6 participants
per group = 10 therapist hours per service user
£1,148
Mindfulness
training
8 group sessions x 2.5 hours each plus an all-day retreat (7.5
hours), 2 therapists & 12 participants per group = 4.58 therapist
hours per service user
£551
GCBT,
Heimberg
12 group sessions x 2.5 hours, 2 therapists & 6 participants per
group = 10 therapist hours per service user
£1,148
GCBT, general 15 group sessions x 2 hours each, 2 therapists & 6 participants per
group = 10 therapist hours per service user
£1,148
IPT 18 individual sessions x 50 min each = 15 therapist hours per
service user
£1,698
PDPT 25 individual sessions x 50 min each = 20.83 therapist hours per
service user
£2,341
Supportive
therapy
14 individual sessions x 1 hour each = 14 therapist hours per
service user
£1,588
ICBT, Hope 16 individual sessions x 1 hour each, with the exception of the ﬁrst
in-session exposure session which lasts 1.5 hours = 16.5 therapist
hours per service user
£1,864
ICBT, C&W 14 individual sessions x 90 min each = 21 therapist hours per
service user
£2,359
ICBT, short 14 individual sessions x 75 min each = 17.5 therapist hours per
service user
£1,974
ICBT, general 16 individual sessions x 1 hour each = 16 therapist hours per
service user
£1,809
Wait list No related resource use £0
aCost of therapists was estimated using the unit cost of Band 7 qualiﬁed clinical psychologists (NHS
Agenda for Change for qualiﬁed Allied Health Professionals), which includes salary, on-costs and
overheads [39]; additional qualiﬁcation costs estimated as a proportion of this unit cost, after examining unit
costs without/with qualiﬁcation costs for other mental health professionals (consultant psychiatrists and
mental health nurses); estimated unit cost for Band 7 therapist equals £110 per hour; total cost per person
includes a GP visit for referral to the psychological service; GP unit cost taken from [38].
C&W: Clark and Wells model; GCBT: group cognitive behavioural therapy; ICBT: individually delivered
cognitive behavioural therapy; IPT: interpersonal therapy; PDPT: psychodynamic psychotherapy; SHNS:
self-help no support; SHWS: self-help with support
doi:10.1371/journal.pone.0140704.t002
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interventions, determined by completion rates and compliance data reported in RCTs included
in the NMA. The same distributions around the number of GP visits were used for all pharma-
cological interventions. The number of therapist sessions per person attending group psycho-
logical interventions was not assigned a probabilistic distribution because the number of group
sessions remains the same, whether a participant attends the full course of treatment or a lower
number of sessions. Drug acquisition costs are not subject to uncertainty and thus were also
not assigned probabilistic distributions. However, if people receiving pharmacological therapy
attended considerably fewer GP visits than the mode, then they were assumed to be prescribed
smaller amounts of medication than optimal, and to subsequently incur lower drug acquisition
costs (either at initial or during maintenance treatment). Uncertainty in intervention costs of
self-help interventions was considered by applying a normal distribution around the time
spent with the therapist.
Table 3 reports the values of all model input parameters and provides details on the types
and range of distributions assigned to each.
Deterministic sensitivity analyses explored the following alternative scenarios:
• self-help interventions to be supported by a Band 5 therapist and group therapies to be deliv-
ered by one Band 7 and one Band 6 therapists (in the base-case analysis all therapists were in
Band 7 according to the NHS Agenda for Change for qualified Allied Health Professionals,
with a unit cost of £110 per hour; Band 6 and Band 5 therapist unit costs were £93 and £87
per hour, respectively) [38,39].
• use of an alternative set of utility scores, based on EQ-5D data [40] derived from a commu-
nity-based mental health European survey [46]. These data reflected a smaller difference in
utility between social anxiety disorder and no mental disorder compared with those used in
the base-case analysis (this scenario used utility values of 0.79 and 0.91 for social anxiety dis-
order and no social anxiety disorder, respectively).
• use of alternative time horizons of 1, 3, and 10 years following the 12 weeks of initial treat-
ment. These scenarios were tested to explore the short-term cost effectiveness of interven-
tions for social anxiety disorder and potential changes in their relative cost effectiveness over
time and in the long term.
• the risk ratio of relapse of drugs versus psychological interventions for year 1 to equal a range
of values between 1.0 and 2.0, as this may be closer to real life than the reported mean value
of 3.0 [31] that was utilised in the economic analysis.
Results
Output of network meta-analysis used in the economic analysis
Results of the NMA that populated the economic model are provided in Table 4, which shows
the probability of recovery at end of treatment for each intervention. Treatments have been
ranked from the most to the least effective; the mean probability of recovery ranged from 0.62
(95% credible intervals 0.16 to 0.95) for ICBT C&W down to 0.10 (95% credible intervals 0.01
to 0.39) for wait list. Overall, the various forms of ICBT showed high probabilities of recovery
(mean value in the range of 0.39–0.62) with other individually delivered psychological thera-
pies being less effective (range of mean probabilities of recovery 0.16–0.26). The mean proba-
bilities of recovery for drugs and self-help interventions were in the range of 0.27 to 0.40, with
the exception of phenelzine, the mean probability of which reached 0.51 (second most effective
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Table 3. Input parameters utilised in the economicmodel of interventions for adults with social anxiety disorder.
Input parameter Mean
value
Probabilistic distribution Source of data—comments
Probability of recovery, all
interventions—end of treatment
See
Table 4
Distribution based on NMA NMA; distribution formed by 10,000 iterations
Annual probability of recovery, all
interventions—years 2–5
0.0377 Beta distribution on 12-year
probability: α = 65; β = 111
[21]
Annual probability of relapse, drugs
—year 1
0.4169 Midpoint between 2 beta
distributions:
Midpoint between pooled relapse rate from drug arms and
pooled relapse rate from pill placebo arms of 5 relapse
prevention RCTs identiﬁed by a systematic literature search [26–
30]
α = 107; β = 293
α = 222; β = 170
Risk ratio of relapse, drugs versus
psychological interventions—year 1
3.00 Log-norm distribution [31]
95% CIs: 0.73 to 12.39
Annual probability of relapse,
allinterventions—years 2–5
0.0409 Beta distribution on 12-year [21]
probability: α = 26; β = 40
Utilities Beta distribution
Recovery (no social anxiety disorder) 0.866 α = 4572; β = 707 Estimated using method of moments, based on published data
in [33]Non-recovery, relapse (social anxiety
disorder)
0.659 α = 40; β = 20
Intervention resource use and costs
Drug acquisition costs & health
professional unit costs
See
Tables 1 &
2
No distribution assigned
Number of GP visits assigned to
pharmacological interventions
Different probabilities assigned
to different numbers of
sessions
Number of visits based on expert opinion; estimated probabilities
based on completion rates reported in large pharmacological
RCTs included in NMA (N>100) and further assumptions. If
number of GP visits in initial treatment equalled 1 or 2, no
maintenance treatment followed. If number of GP visits in initial
treatment equalled 1, only 50% of the 12-week drug acquisition
costs were incurred; if number of GP visits equalled zero in
maintenance treatment, no 26-week drug acquisition costs were
considered
Initial treatment (12 weeks) 4 65%: 4; 10%: 3, 5 or 6; 25%: 1
or 2
Maintenance treatment (26 weeks) 3 55%: 3; 45%: 0 or 1 or 2 or 4
Number of sessions in individually
delivered psychological
interventions
Different probabilities assigned
to different numbers of session
IPT 18 70%: 18; 15%: 14–17; 15%:
1–13
Number of sessions and estimated
PDPT 25 70%: 25; 15%: 21–24; 15%:
1–20
probabilities based on number of sessions
Supportive therapy 14 70%: 14; 15%: 10–13; 15%:
1–9
and completion rates reported in
ICBT, general 16 70%: 16; 15%: 12–15; 15%:
1–11
respective RCTs included in NMA and
ICBT, Hope 16 70%: 16; 15%: 12–15; 15%:
1–11
further assumptions.
ICBT, C&W 14 80%: 14; 20%: 10–13
ICBT, short 14 70%: 14; 15%: 10–13; 15%:
1–9
Number of sessions in group
psychological interventions
As in
Table 2
No distribution assigned Participants missing one or more sessions assumed not to be
replaced by others; therefore changes in number of sessions did
not affect total intervention cost.
Time spent with therapist in self-
help (minutes)
Normal distribution Mean contact time based on data reported in relevant clinical
studies; distributionbased on assumption
SHNS (book or internet) 75 SD: 0.3 of the mean
SHWS (book or internet) 210 SD: 0.3 of the mean
(Continued)
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option following ICBT C&W). The mean probabilities of recovery for group psychological
therapies ranged from 0.19 (mindfulness) to 0.34 (GCBT general).
Cost effectiveness
ICBT C&W was the most cost-effective intervention for adults with social anxiety disorder,
with the highest NMB at the NICE lower cost effectiveness threshold of £20,000/QALY [47],
despite having the highest intervention cost. The second most cost-effective option was ICBT
general, while other forms of ICBT, i.e. ICBT Hope and ICBT short ranked 6th and 9th, respec-
tively. Phenelzine ranked 3rd, while book-based self-help without / with support ranked 4th and
5th, respectively. Group-based psychological interventions were not particularly cost-effective
relative to other treatments, ranking in places between 11th and 17th, except mindfulness train-
ing, which ranked 23rd. Drugs (apart from phenelzine) also tended to rank low in terms of cost
effectiveness, taking up places between 8th and 22nd; following phenelzine, the order of the next
most cost-effective drugs was: paroxetine, venlafaxine, fluvoxamine, sertraline, escitalopram
and fluoxetine. Internet-based self-help ranked 7th (with support) and 20th (without support).
Psychodynamic psychotherapy ranked 25th, just above wait list; interpersonal psychotherapy
ranked 27th while supportive therapy was the least cost-effective intervention, ranking in the
last (28th) place. Table 5 provides the mean total costs and QALYs per person and the percent-
age of adults that are well (no social anxiety disorder) at 5 years for each intervention assessed
in the economic analysis; it also provides the results of incremental analysis, the mean NMB of
each intervention at the NICE lower cost effectiveness threshold (£20,000/QALY), and the
ranking of interventions according to their mean NMB. Detailed probabilistic results, including
95% credible intervals of costs, QALYs and NMB of each intervention, the mean ranking of
each intervention and its probability of being cost-effective are provided in S1 Table.
The cost effectiveness plane (Fig 2) shows the incremental costs and QALYs of all interven-
tions versus wait list (placed at the origin). The cost-effectiveness efficiency frontier (continu-
ous line) links all interventions that are not dominated by absolute or extended dominance and
are thus cost-effective at different cost effectiveness thresholds. The slope of the dotted line
indicates the NICE lower cost effectiveness threshold, suggesting that IPT and supportive ther-
apy are not cost-effective compared with wait list (since both lie on the left of the dotted line).
According to the cost-effectiveness acceptability frontier (Fig 3), for cost effectiveness
thresholds between zero and £1,472/QALY, book-based self-help without support has the high-
est NMB (i.e. it is the most cost-effective treatment), but its probability of being cost-effective
does not exceed 0.24. Phenelzine is the most cost-effective intervention for cost effectiveness
thresholds between £1,472/QALY and £9,179/QALY, with a maximum probability of cost
effectiveness just above 0.38. At even higher cost effectiveness thresholds, ICBT (C&W) has the
Table 3. (Continued)
Input parameter Mean
value
Probabilistic distribution Source of data—comments
Annual health and social care cost Gamma distribution
Recovery (no social anxiety disorder) £645 SE: £93 [6]
Non-recovery, relapse (social anxiety
disorder)
£1,037 SE: £209 [6]
Annual discount rate 0.035 No distribution assigned [42]
C&W: Clark and Wells model; ICBT: individually delivered cognitive behavioural therapy; IPT: interpersonal therapy; NMA: network meta-analysis; PDPT:
psychodynamic psychotherapy; SHNS: self-help no support; SHWS: self-help with support
doi:10.1371/journal.pone.0140704.t003
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highest NMB and a probability of cost effectiveness that increases with increasing cost effec-
tiveness thresholds. The probability of ICBT (C&W) being cost-effective reaches 0.68 at the
NICE £20,000/QALY threshold of and goes beyond 80% when the threshold exceeds £32,500/
QALY.
Results were robust to use of lower unit costs for therapists involved in self-help and group
psychological interventions and the use of more conservative utility data. ICBT (C&W)
remained the most cost-effective intervention under these scenarios, and the cost effectiveness
ranking of interventions was broadly the same. Sensitivity analysis of different time horizons
indicated that, in the short-term, pharmacological interventions are overall more cost-effective
Table 4. Results of network meta-analysis that were utilised in the economic model: probability of
recovery at end of treatment. Interventions ranked according to probability of recovery (highest to lowest).
Intervention Probability of recovery
mean median 95% credible intervals
ICBT, C&W 0.62 0.65 0.16 to 0.95
Phenelzine 0.51 0.51 0.09 to 0.91
ICBT, general 0.47 0.46 0.08 to 0.90
ICBT, Hope 0.41 0.38 0.06 to 0.86
Paroxetine 0.40 0.37 0.06 to 0.85
ICBT, short 0.39 0.36 0.05 to 0.84
Venlafaxine 0.38 0.35 0.05 to 0.84
Fluvoxamine 0.37 0.34 0.05 to 0.84
Sertraline 0.37 0.33 0.04 to 0.83
Escitalopram 0.35 0.31 0.04 to 0.82
SHWS, internet 0.35 0.31 0.05 to 0.80
Fluoxetine 0.35 0.31 0.04 to 0.81
SHWS, book 0.34 0.30 0.04 to 0.81
GCBT, general 0.34 0.30 0.04 to 0.80
SHNS, book 0.34 0.30 0.04 to 0.80
Citalopram 0.34 0.29 0.04 to 0.82
Exposure 0.33 0.29 0.04 to 0.79
Mirtazapine 0.33 0.28 0.03 to 0.83
GCBT, Heimberg 0.32 0.28 0.04 to 0.78
Moclobemide 0.30 0.25 0.03 to 0.76
Pregabaline 0.29 0.25 0.03 to 0.77
SHWS, book 0.27 0.22 0.03 to 0.73
PDPT 0.26 0.21 0.03 to 0.72
Pill placebo 0.21 0.16 0.02 to 0.64
IPT 0.20 0.15 0.02 to 0.64
Mindfulness 0.19 0.14 0.02 to 0.63
Supportive therapy 0.16 0.11 0.01 to 0.57
Wait list 0.10 0.07 0.01 to 0.39
The log-odds of recovery on wait list was assumed to follow a normal distribution with mean -2.629 and
variance 1.235 (estimated using all the wait list arms of RCTs included in the NMA); this translates into a
probability of recovery for wait list (mean, 95% credible intervals) as shown above.
C&W: Clark and Wells model; GCBT: group cognitive behavioural therapy; ICBT: individually delivered
cognitive behavioural therapy; IPT: interpersonal therapy; NMA: network meta-analysis; PDPT:
psychodynamic psychotherapy; SHNS: self-help no support; SHWS: self-help with support
doi:10.1371/journal.pone.0140704.t004
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than psychological interventions. At a 1-year time horizon, phenelzine produced the highest
NMB and was the most cost-effective among treatment options, whereas ICBT (C&W) ranked
only 17th. Of the first 10 places in ranking, 8 were occupied by pharmacological interventions
and the remaining 2 were occupied by book-based self-help (without / with support). However,
by 3 years ICBT (C&W) became the most cost-effective intervention followed by phenelzine.
The relative cost effectiveness of drugs was reduced compared with their cost effectivess at a
1-year time horizon; in constrast, the cost effectiveness of psychological interventions
improved, whereas the cost effectiveness of book-based self-help remained broadly the same.
By 10 years, the ranking of interventions by cost effectiveness mirrored their ranking by effec-
tiveness (number of QALYs), with the 4 individual forms of CBT occupying the 4 first places
Table 5. Cost effectiveness of interventions for adults with social anxiety disorder: results of probabilistic analysis. Mean values per person 5
years after end of treatment.
Intervention % without SA at 5
years
Mean
QALYs
Mean total
costs (£)
Incremental analysis & ICERs
(£/QALY)
Mean NMB
(£)
Ranking by highest
NMB
ICBT, C&W 50.25 3.75 6,178 9,179 versus phenelzine 68,810 1
ICBT, general 41.40 3.64 5,714 Extendendly dominateda 67,040 2
ICBT, Hope 37.52 3.59 5,853 Dominated 65,916 6
ICBT, short 36.25 3.57 5,970 Dominated 65,479 9
Phenelzine 34.80 3.57 4,557 1,472 versus SHNS book 66,899 3
SHWS, internet 34.02 3.54 5,186 Dominated 65,699 7
SHWS, book 33.59 3.54 4,741 Dominated 66,037 5
GCBT, general 33.54 3.54 5,436 Dominated 65,327 11
SHNS, book 33.28 3.53 4,501 66,197 4
Exposure 33.00 3.53 5,448 Dominated 65,179 14
GCBT, Heimberg 32.40 3.52 5,463 Dominated 65,013 17
Paroxetine 30.01 3.51 4,561 Dominated 65,603 8
Venlafaxine 29.46 3.50 4,633 Dominated 65,380 10
Fluvoxamine 29.08 3.50 4,666 Dominated 65,245 12
Sertraline 28.75 3.49 4,583 Dominated 65,239 13
SHNS, internet 29.55 3.49 5,042 Dominated 64,714 20
Escitalopram 28.12 3.48 4,591 Dominated 65,058 15
Fluoxetine 27.98 3.48 4,597 Dominated 65,016 16
PDPT 28.80 3.48 6,509 Dominated 63,055 25
Citalopram 27.53 3.47 4,602 Dominated 64,890 18
Mirtazapine 27.18 3.47 4,611 Dominated 64,786 19
Moclobemide 25.95 3.45 4,740 Dominated 64,323 21
Pregabalin 25.78 3.45 4,898 Dominated 64,118 22
IPT 25.44 3.44 5,987 Dominated 62,728 27
Mindfulness 24.86 3.43 5,041 Dominated 63,527 23
Pill placebo 22.29 3.40 4,713 Dominated 63,360 24
Supportive
therapy
22.89 3.40 5,934 Dominated 62,136 28
Wait list 20.43 3.37 4,593 Dominated 62,810 26
aExtended dominance occurs when an option is less effective and more costly than a linear combination of two alternative options.
Interventions have been ranked from the most to least effective according to the number of QALYs gained.
C&W: Clark and Wells model; GCBT: group cognitive behavioural therapy; ICBT: individually delivered cognitive behavioural therapy; ICER: Incremental
Cost Effectiveness Ratio; IPT: interpersonal therapy; NMB: Net Monetary Beneﬁt, estimated using a willingeness to pay £20,000/QALY; PDPT:
psychodynamic psychotherapy; SA: Social Anxiety disorder; SHNS: self-help no support; SHWS: self-help with support.
doi:10.1371/journal.pone.0140704.t005
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in ranking due to their higher intervention costs having been fully offset by health and personal
social service cost-savings.
As expected, use of lower risk ratios of relapse for drugs versus psychological interventions
favoured drugs. When an equal risk of relapse was assumed, phenelzine became the most cost-
effective intervention and, with the exception of ICBT (C&W) which ranked 2nd, the rest top-5
places in cost effectiveness ranking were occupied by drugs. However, ICBT (C&W) became
the most cost-effective option when the risk ratio of relapse rose at just 1.15, and performance
of psychological interventions improved substantially with increasing values of this ratio. For
example, at a value of 1.5, 3 psychological interventions (ICBT, C&W; ICBT, general and
SHNS, book) ranked in the top-5 places, while at a risk ratio of 2, the 5 most cost-effective
options included 4 psychological interventions and phenelzine, with overall results being
broadly consistent with those of the base-case analysis.
Fig 2. Cost-effectiveness plane showing the incremental costs and QALYs of all interventions versus
wait list.Wait list is placed at the origin; results are for 1,000 adults with social anxiety disorder at 5 years
after treatment. The continuous line shows the cost-effectiveness efficiency frontier, while the slope of the
dotted line indicates the NICE lower cost effectiveness threshold (£20,000/QALY). The data used to
construct Fig 2 are provided in Table 5.
doi:10.1371/journal.pone.0140704.g002
Fig 3. Cost-effectiveness acceptability frontier of pharmacological and psychological interventions
for adults with social anxiety disorder. The values used to construct Fig 3 are provided in S2 Table.
doi:10.1371/journal.pone.0140704.g003
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Results of deterministic one-way sensitivity analyses are provided in S3 File. The determin-
istic ranking of interventions according to cost effectiveness for different time horizons tested
is provided in S3 Table. The deterministic ranking of interventions according to cost effective-
ness at different values of the risk ratio of relapse of drugs versus psychological interventions
(year 1) is shown in S4 Table.
Discussion
Individual forms of CBT appear to be the most cost-effective interventions for adults with
social anxiety disorder. Self-help, in particular book-based, is cost-effective compared with
other options. Group-based psychological interventions and drugs (with the exception of phe-
nelzine, which was among the most cost-effective options) do not appear to be particularly
cost-effective relative to other treatments. Other individually delivered psychological interven-
tions such as psychodynamic psychotherapy, interpersonal therapy and supportive therapy are
the least cost-effective options for adults with social anxiety disorder. The emergence of indi-
vidual forms of CBT as most cost-effective options despite their high intervention costs is
attributed to two factors: their higher effectiveness compared with other interventions and the
considerably lower risk of relapse of psychological interventions compared with drugs; conse-
quently these interventions result in higher health benefits (QALYs), but also in a reduction in
health and personal social service costs attributable to social anxiety disorder. Moreover, the
cost effectiveness of individual forms of CBT appears to increase over time because their high
intervention costs (which are responsible for the low performance of these interventions 1 year
after treatment) are spread over a longer time period and are offset to a greater extent by health
and personal social service cost savings associated with the successful management of social
anxiety disorder.
Strengths and limitations
The bigest strength of our analysis is the utilisation of efficacy data derived from a systematic
literature review and NMA. This methodology enabled us to consider information from both
direct and indirect comparisons between interventions, and allowed simultaneous inference on
all treatment options examined in trial pair-wise comparisons while preserving randomisation
[20,48]. This approach for evidence synthesis is essential for populating model-based economic
studies assessing more than two competing interventions. The NMA principally utilised con-
tinuous data to estimate the relative treatment effects of interventions, and then transformed
the estimated SMDs into probabilities of recovery. Such a transformation is valid as long as the
assumed relationship between the treatment effect based on continuous data and the treatment
effect estimated using recovery data holds. This assumption could not be checked for all inter-
ventions, but available data indicated a strong relationship and therefore this transformation is
unlikely to have introduced substantial bias into the analysis [14]. These assumptions along
with the limitations of the NMAmodel and the limitations of the RCTs considered in the
NMA [14] may have impacted on the quality of the respective input parameters used to popu-
late the economic model.
A number of interventions such as benzodiazepines, anticonvulsants and combination ther-
apies that were included in the NMA [14] were not considered in the economic analysis. Ben-
zodiazepines cannot be used beyond 2–4 weeks for the treatment of anxiety [36]. Clinical
evidence on anticonvulsants and combination therapies was particularly limited and overall of
low quality [14] so that inclusion of these interventions in the analysis would not have impor-
tant implications for decision making.
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An important limitation of the economic analysis was the poor quality of the relapse data
used, due to lack of robust evidence on the relative risk of relapse between pharmacological
and psychological interventions for social anxiety disorder. Furthermore, due to lack of inter-
vention-specific data, the economic model assumed one (common) risk of relapse applied to
all pharmacological interventions, and one (common) risk of relapse across all psychological
ones. Nevertheless, evidence suggests that, in constrast to pharmacological interventions,
which are characterised by a relatively high relapse risk at 6 months of maintenance treatment
[26–30], the effect of psychological interventions is well-maintained in the long-term, after end
of treatment [49,50]. Moreover, the mean probabilities of relapse for drugs and psychological
interventions estimated for the economic model (42% versus 14%, respectively) are similar to
relapse rates reported in trials of these types of therapies for social anxiety disorder, very close
to respective relapse rates reported for people with obsessive compulsive disorder (45% versus
12%, respectively) [51] and broadly consistent with respective figures reported for panic disor-
der (40% versus 5%, respectively) [52]. Sensitivity analysis showed that more conservative
assumptions regarding the superiority of psychological interventions over drugs in retaining
long-term effects would lead to broadly the same conclusions.
Another limitation of the economic analysis was the lack of consideration of the impact of
the side effects of drugs on the HRQoL and costs, due to inconsistent reporting of side effect
data in the RCTs included in the NMA. In particular, use of phenelzine, which was ranked 3rd
most cost-effective intervention, is associated with a potentially dangerous interaction with
foods containing tyramine that may lead to episodes of high blood pressure, thus imposing die-
tary restrictions to people administered this drug. Omission of the impact of drug-related side
effects from the economic model has likely overestimated the cost effectiveness of all pharma-
cological interventions. Other limitations of the model include the use of utility data that were
not specific to health states of social anxiety disorder and the use of resource use data associated
with social anxiety disorder collected almost 20 years ago, due to lack of better quality and
more up-to-date data, respectively.
Comparison with other published studies in the field
Published economic analyses have explored the cost-effectiveness of a very limited range of
interventions for social anxiety disorder and concluded that escitalopram [53], group CBT
[54–56] and computer-based self-help [55–57] are cost-effective options. All studies were char-
acterised by methodological limitations, such as exclusive consideration of intervention costs
and omission of other relevant healthcare [54,57] or equipment (computer) [55–57] costs, an
inability to accurately record relevant healthcare costs from all study participants [53], and
inappropriate estimation of the relative effectiveness of interventions, by utilising their effect
sizes versus different controls (waitlist or pill placebo), so that the effect sizes were not compa-
rable [54]. Therefore, these findings should be treated with caution.
Generalisability of the results and implications of the study
Our analysis has been conducted from the perspective of the British NHS and Personal Social
Services. Results are likely generalisable to other settings with similar funding and structure of
healthcare and personal social services and comparable care pathways for social anxiety disor-
der. It should be noted that conclusions on cost effectiveness ultimately rely on the cost effec-
tiveness threshold adopted, and this depends on the policy makers’ willingness-to-pay for
treatment benefits, which may vary across countries and health systems. The economic model
did not incorporate productivity losses. However, more effective interventions can reasonably
be expected to lead to improved functioning, and, in turn, to increased employment rates and
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reduced days of sick leave, thus to an increase in productivity gains. Consequently, consider-
ation of productivity losses in our analysis would probably further favour individual forms of
CBT.
Based on our findings and after considering potential drug interactions (fluvoxamine), side
effects that were not considered in the model (such as possible blood pressure changes with
venlafaxine and phenelzine, discontinuation symptoms associated with venlafaxine and SSRIs
and in particular with paroxetine), dietary restrictions with the MAOIs, the limited evidence
base for fluoxetine relative to other drugs, and concerns about the quality of phenelzine data
which may have led to overestimation of the drug’s effect, the NICE clinical guideline on social
anxiety disorder recommended individually delivered CBT that has been specifically designed
for social anxiety disorder as first line treatment for adults with social anxiety disorder [15].
Supported self-help was recommended as second-line psychological treatment, while SSRIs
(escitalopram or sertraline) were recommended for people preferring pharmacological treat-
ment. Additional recommendations were made for people not responding or partially respond-
ing to treatment and for those developing side effects. Further good quality research is needed
on the comparative long-term outcomes of psychological and pharmacological interventions
as well as on costs and utility values associated with social anxiety disorder, in order to establish
the relative cost effectiveness of interventions for social anxiety disorder with greater certainty.
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